BETHESDA, Md.--(BUSINESS WIRE)--Aug. 1, 2006--RegeneRx Biopharmaceuticals (AMEX:RGN) reported today that researchers at the National Institutes of Health (NIH) found that TB4, administered to wounds in laboratory animals, significantly increased several important wound healing proteins called matrix metalloproteinases (MMPs), including MMP-2 and MMP-9. The researchers surmised that it is likely that other proteinases may also be regulated (up or down) by TB4. The paper, Thymosin B4 Promotes Matrix Metalloproteinase Expression During Wound Repair, was published in the Journal of Cellular Physiology, (D. Philp, et al., 208:195:200; 2006).
